Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7%

Spark Therapeutics, Inc. ONCE was a big mover last session, as the company saw its shares rise above 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $58.13 to $65.56 in the past one-month time frame.

The company has seen no positive or negative estimate revision in the past 30 days. But its Zacks Consensus Estimate moved higher over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
 
Spark Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is positive.

Spark Therapeutics, Inc. Price

 

A better-ranked stock in the Medical - Biomedical and Genetics industry is AMAG Pharmaceuticals, Inc. AMAG, which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

More Stock News: This Is Bigger than the iPhone!                   
                                                                                                                     
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
                                                                                                                     
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report
 
Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research